Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. grew its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 116,200 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,100 shares during the period. Hillsdale Investment Management Inc. owned about 0.36% of Collegium Pharmaceutical worth $3,329,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares in the last quarter. Penserra Capital Management LLC acquired a new position in Collegium Pharmaceutical during the third quarter worth $757,000. Barclays PLC raised its position in Collegium Pharmaceutical by 152.2% in the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after acquiring an additional 45,291 shares in the last quarter. Sanctuary Advisors LLC raised its position in Collegium Pharmaceutical by 10.7% in the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after acquiring an additional 1,731 shares in the last quarter. Finally, FMR LLC lifted its holdings in Collegium Pharmaceutical by 1,532.2% in the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after acquiring an additional 35,439 shares during the period.

Collegium Pharmaceutical Price Performance

COLL stock opened at $30.05 on Friday. The stock’s 50 day moving average price is $30.69 and its 200 day moving average price is $32.67. The firm has a market cap of $946.15 million, a P/E ratio of 12.95 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 1 year low of $27.28 and a 1 year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. On average, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 10,445 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares of the company’s stock, valued at $4,959,032.46. This represents a 5.95 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. This trade represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,193 shares of company stock valued at $3,243,594 in the last ninety days. Insiders own 3.98% of the company’s stock.

Wall Street Analyst Weigh In

COLL has been the subject of a number of research analyst reports. Piper Sandler reduced their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Finally, Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.